Non-Invasive Prenatal Testing (NIPT) Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
Report Code: KNJ594152 No. of Pages: 129 Category: Medical Devices
Publisher: Date of Publish:
Publisher: Date of Publish:
Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Non-Invasive Prenatal Testing (NIPT) market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Non-Invasive Prenatal Testing (NIPT) market segmented into
Ultrasound Detection
Biochemical Screening Tests
Cell-Free Dna In Maternal Plasma Tests
Fetal Cells In Maternal Blood Tests
Others
Based on the end-use, the global Non-Invasive Prenatal Testing (NIPT) market classified into
Hospitals
Clinics
Research Laboratories
Based on geography, the global Non-Invasive Prenatal Testing (NIPT) market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
GE Healthcare
Koninklijke Philips
BGI Genomics
Illumina
Thermo Fisher Scientific
F. Hoffmann-La Roche
Pacific Biosciences Of California
Perkinelmer
Qiagen
Agilent Technologies
LifeCodexx
Berry Genomics
LifeLabs Genetics
Quest Diagnostics
Safembryo
Laboratory Corporation of America Holdings
Natera
Sequenom
Ariosa Diagnostics
CombiMatrix Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) INDUSTRY
2.1 Summary about Non-Invasive Prenatal Testing (NIPT) Industry
2.2 Non-Invasive Prenatal Testing (NIPT) Market Trends
2.2.1 Non-Invasive Prenatal Testing (NIPT) Production & Consumption Trends
2.2.2 Non-Invasive Prenatal Testing (NIPT) Demand Structure Trends
2.3 Non-Invasive Prenatal Testing (NIPT) Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Ultrasound Detection
4.2.2 Biochemical Screening Tests
4.2.3 Cell-Free Dna In Maternal Plasma Tests
4.2.4 Fetal Cells In Maternal Blood Tests
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Research Laboratories
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Ultrasound Detection
5.2.2 Biochemical Screening Tests
5.2.3 Cell-Free Dna In Maternal Plasma Tests
5.2.4 Fetal Cells In Maternal Blood Tests
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Research Laboratories
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Ultrasound Detection
6.2.2 Biochemical Screening Tests
6.2.3 Cell-Free Dna In Maternal Plasma Tests
6.2.4 Fetal Cells In Maternal Blood Tests
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Research Laboratories
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Ultrasound Detection
7.2.2 Biochemical Screening Tests
7.2.3 Cell-Free Dna In Maternal Plasma Tests
7.2.4 Fetal Cells In Maternal Blood Tests
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Research Laboratories
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Ultrasound Detection
8.2.2 Biochemical Screening Tests
8.2.3 Cell-Free Dna In Maternal Plasma Tests
8.2.4 Fetal Cells In Maternal Blood Tests
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Research Laboratories
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Ultrasound Detection
9.2.2 Biochemical Screening Tests
9.2.3 Cell-Free Dna In Maternal Plasma Tests
9.2.4 Fetal Cells In Maternal Blood Tests
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Research Laboratories
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 GE Healthcare
10.1.2 Koninklijke Philips
10.1.3 BGI Genomics
10.1.4 Illumina
10.1.5 Thermo Fisher Scientific
10.1.6 F. Hoffmann-La Roche
10.1.7 Pacific Biosciences Of California
10.1.8 Perkinelmer
10.1.9 Qiagen
10.1.10 Agilent Technologies
10.1.11 LifeCodexx
10.1.12 Berry Genomics
10.1.13 LifeLabs Genetics
10.1.14 Quest Diagnostics
10.1.15 Safembryo
10.1.16 Laboratory Corporation of America Holdings
10.1.17 Natera
10.1.18 Sequenom
10.1.19 Ariosa Diagnostics
10.1.20 CombiMatrix
10.2 Non-Invasive Prenatal Testing (NIPT) Sales Date of Major Players (2017-2020e)
10.2.1 GE Healthcare
10.2.2 Koninklijke Philips
10.2.3 BGI Genomics
10.2.4 Illumina
10.2.5 Thermo Fisher Scientific
10.2.6 F. Hoffmann-La Roche
10.2.7 Pacific Biosciences Of California
10.2.8 Perkinelmer
10.2.9 Qiagen
10.2.10 Agilent Technologies
10.2.11 LifeCodexx
10.2.12 Berry Genomics
10.2.13 LifeLabs Genetics
10.2.14 Quest Diagnostics
10.2.15 Safembryo
10.2.16 Laboratory Corporation of America Holdings
10.2.17 Natera
10.2.18 Sequenom
10.2.19 Ariosa Diagnostics
10.2.20 CombiMatrix
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com